Tarsus Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US87650L1035

Introduction

This page provides a comprehensive analysis of the known insider trading history of Whitfield Dianne C.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Whitfield Dianne C. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:TARS / Tarsus Pharmaceuticals, Inc. Chief Human Resources Officer 46,355
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Whitfield Dianne C.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases TARS / Tarsus Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in TARS / Tarsus Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TARS / Tarsus Pharmaceuticals, Inc. Insider Trades
Insider Sales TARS / Tarsus Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in TARS / Tarsus Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-03-20 TARS Whitfield Dianne C. 2,137 50.1100 2,137 50.1100 107,085 133 38.8200 -24,127 -22.53
2025-03-19 TARS Whitfield Dianne C. 2,259 47.4000 2,259 47.4000 107,077
2025-03-18 TARS Whitfield Dianne C. 2,315 46.2900 2,315 46.2900 107,161
2024-03-18 TARS Whitfield Dianne C. 4,314 30.6000 4,314 30.6000 132,008
2023-11-30 TARS Whitfield Dianne C. 8,355 16.3100 8,355 16.3100 136,270
2023-03-23 TARS Whitfield Dianne C. 345 12.1500 345 12.1500 4,192
2023-03-22 TARS Whitfield Dianne C. 333 12.6400 333 12.6400 4,209
2023-03-21 TARS Whitfield Dianne C. 326 12.8900 326 12.8900 4,202
2023-03-20 TARS Whitfield Dianne C. 333 12.6100 333 12.6100 4,199
2023-03-17 TARS Whitfield Dianne C. 316 13.2800 316 13.2800 4,196
2023-03-16 TARS Whitfield Dianne C. 313 13.4300 313 13.4300 4,204
2022-12-02 TARS Whitfield Dianne C. 1,154 16.9000 1,154 16.9000 19,503
2022-12-01 TARS Whitfield Dianne C. 1,165 16.7500 1,165 16.7500 19,514
2022-11-30 TARS Whitfield Dianne C. 1,182 16.5000 1,182 16.5000 19,503

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TARS / Tarsus Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Whitfield Dianne C. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-20 2025-03-20 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -2,137 46,355 -4.41 50.11 -107,085 2,322,849
2025-03-20 2025-03-19 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -2,259 48,492 -4.45 47.40 -107,077 2,298,521
2025-03-20 2025-03-18 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -2,315 50,751 -4.36 46.29 -107,161 2,349,264
2025-03-18 2025-03-15 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
M - Exercise 18,885 53,066 55.25
2024-03-19 2024-03-18 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -4,314 34,181 -11.21 30.60 -132,008 1,045,939
2024-03-19 2024-03-15 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
M - Exercise 11,711 38,495 43.72
2023-12-01 2023-11-30 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -8,355 26,784 -23.78 16.31 -136,270 436,847
2023-12-01 2023-11-29 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
M - Exercise 23,920 35,139 213.21
2023-03-23 2023-03-23 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -345 11,219 -2.98 12.15 -4,192 136,311
2023-03-23 2023-03-22 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -333 11,564 -2.80 12.64 -4,209 146,169
2023-03-23 2023-03-21 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -326 11,897 -2.67 12.89 -4,202 153,352
2023-03-21 2023-03-20 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -333 12,223 -2.65 12.61 -4,199 154,132
2023-03-21 2023-03-17 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -316 12,556 -2.45 13.28 -4,196 166,744
2023-03-17 2023-03-16 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -313 12,872 -2.37 13.43 -4,204 172,871
2023-03-17 2023-03-15 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
M - Exercise 4,462 13,185 51.15
2022-12-06 2022-12-02 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -1,154 8,723 -11.68 16.90 -19,503 147,419
2022-12-01 2022-12-01 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -1,165 9,877 -10.55 16.75 -19,514 165,440
2022-12-01 2022-11-30 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
S - Sale -1,182 11,042 -9.67 16.50 -19,503 182,193
2022-12-01 2022-11-29 4 TARS Tarsus Pharmaceuticals, Inc.
Common Stock
M - Exercise 10,251 12,224 519.56
2022-03-11 2022-03-09 4 TARS Tarsus Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 34,171 34,171
2022-03-11 2022-03-09 4 TARS Tarsus Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 17,850 17,850
2022-03-11 2022-03-09 4 TARS Tarsus Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 60,846 60,846
2021-01-08 2021-01-07 4 TARS Tarsus Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 89,368 89,368
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)